A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Pfizer
Sun Yat-sen University
Pfizer
Institut du Cancer de Montpellier - Val d'Aurelle
Universitätsmedizin Mannheim
Memorial Sloan Kettering Cancer Center
Canadian Cancer Trials Group
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)
Rutgers, The State University of New Jersey
Jonsson Comprehensive Cancer Center
City of Hope Medical Center
Institut Bergonié
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
Pfizer
Servicio de Salud Metropolitano Sur Oriente
City of Hope Medical Center
Memorial Sloan Kettering Cancer Center
Ohio State University Comprehensive Cancer Center
Ohio State University Comprehensive Cancer Center
Ohio State University Comprehensive Cancer Center
Asan Medical Center
Fudan University
Goethe University
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Canadian Cancer Trials Group
Eastern Cooperative Oncology Group
Eastern Cooperative Oncology Group
Eastern Cooperative Oncology Group
AIO-Studien-gGmbH
Fujian Cancer Hospital
Federation Francophone de Cancerologie Digestive
University of Southern California
Grupo Espanol Multidisciplinario del Cancer Digestivo
SCRI Development Innovations, LLC
UNC Lineberger Comprehensive Cancer Center
University of Maryland, Baltimore
Medical Research Council
Medical Research Council
Virginia Commonwealth University
Grupo Espanol Multidisciplinario del Cancer Digestivo
Fox Chase Cancer Center
UNICANCER
Washington University School of Medicine
UNICANCER
UNICANCER